Significant decrease in the prevalence of hepatitis C infection after the introduction of direct acting antivirals

J Gastroenterol Hepatol. 2020 Sep;35(9):1570-1578. doi: 10.1111/jgh.14984. Epub 2020 Feb 4.

Abstract

Background and aim: Accurate information on the epidemiology of hepatitis C and B infection is mandatory to establish a national/regional plan. We aim to update the prevalence of hepatitis C and B infection in Catalonia using point-of-care tests to analyze the risk factors related and to implement a linkage-to-care circuit.

Methods: This is a community-based study. A random list of adult individuals was retrieved from censuses of primary care centers. Point-of-care tests for anti-hepatitis C virus (HCV) and HBV surface antigen (HBsAg) and a questionnaire for risk factor assessment were performed. Positive results were validated and a circuit for linkage-to-care was established.

Results: A total of 3328 individuals were included. The anti-HCV and HBsAg overall prevalence were lower than expected [1.02%, 95% confidence interval (CI) 0.65-1.39; and 0.52%, 95% CI 0.26-0.77, respectively]. Anti-HCV positive subjects were mostly (88%) autochthonous. The prevalence increased with age; only 12% were under age 40. The associated risk factors were drug use, blood transfusion, relative with HCV, and diabetes. Notably, the prevalence of active infection was only 0.49% (95% CI 0.23-0.74), 40% less than previously reported, reflecting the impact of direct acting antiviral therapy. Differently, HBsAg positive subjects were mostly foreign migrants (53%) with no other risk factors. Despite the implementation of a linkage-to-care circuit, one third of HBsAg positive subjects were lost.

Conclusions: The prevalence of HCV infection was lower than previously reported, showing a strong impact of direct acting antiviral therapy in the last years. Because of hepatitis B universal vaccination, HBV infection in Catalonia is mainly associated with migrant population. Linkage-to-care in patients with hepatitis B was challenging and warrants additional efforts.

Keywords: Hepatitis C; hepatitis B; point-of-care testing; prevalence; risk factors.

MeSH terms

  • Administration, Oral
  • Adult
  • Age Factors
  • Aged
  • Aged, 80 and over
  • Antiviral Agents / administration & dosage*
  • Biomarkers / blood
  • Female
  • Hepatitis B / diagnosis*
  • Hepatitis B / drug therapy
  • Hepatitis B / epidemiology
  • Hepatitis B Surface Antigens / blood
  • Hepatitis C / diagnosis*
  • Hepatitis C / drug therapy
  • Hepatitis C / epidemiology*
  • Hepatitis C Antibodies / blood
  • Humans
  • Male
  • Middle Aged
  • Point-of-Care Testing
  • Prevalence
  • Risk Factors
  • Spain / epidemiology
  • Surveys and Questionnaires

Substances

  • Antiviral Agents
  • Biomarkers
  • Hepatitis B Surface Antigens
  • Hepatitis C Antibodies